← Back to Search

Janus Kinase (JAK) Inhibitor

Baricitinib for Long COVID (REVERSE-LC Trial)

Phase 3
Waitlist Available
Led By E. Wesley Ely, MD, MPH
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female, aged ≥18 years old
Ability to take oral medication and be willing to adhere to the baricitinib regimen
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

REVERSE-LC Trial Summary

This trial tests a drug to help adults w/Alzheimer's/ADRD & Long COVID symptoms. It will compare the drug to placebo to see if it works.

Who is the study for?
Adults over 18 who had COVID-19 at least 6 months ago, with ongoing neurocognitive or cardiopulmonary symptoms for 60+ days. Must be able to take oral meds and follow the study plan, including contraception if applicable. Excludes those currently infected, on certain drugs like DMARDs, with a history of serious infections or conditions like tuberculosis, HIV, cancer, severe liver disease; also excludes pregnant/breastfeeding individuals.Check my eligibility
What is being tested?
The pilot study is testing Baricitinib (4 MG), an oral medication against placebo in adults suffering from long-term cognitive or heart/lung issues after COVID-19. It's part of a larger phase 3 trial focusing on Long COVID treatment effectiveness.See study design
What are the potential side effects?
Baricitinib may cause side effects such as infection risks due to immune system changes, blood clots, liver enzyme elevations indicating potential liver injury, cholesterol increases which could affect heart health and possible allergic reactions.

REVERSE-LC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I can take pills and will follow the medication plan.
Select...
I have cognitive issues affecting my daily activities.

REVERSE-LC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse event reporting
Diversity in enrollment
Enrollment
+4 more
Secondary outcome measures
Cardiopulmonary testing
Everyday Cognition
Functional Status
+9 more

REVERSE-LC Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention #1Experimental Treatment1 Intervention
These participants will receive baricitinib 4 mg daily for 24 weeks
Group II: PlaceboPlacebo Group2 Interventions
These participants will receive placebo for 24 weeks (6 mo)

Find a Location

Who is running the clinical trial?

University of MinnesotaOTHER
1,378 Previous Clinical Trials
1,587,959 Total Patients Enrolled
University of California, San FranciscoOTHER
2,503 Previous Clinical Trials
15,236,105 Total Patients Enrolled
Yale UniversityOTHER
1,847 Previous Clinical Trials
2,737,118 Total Patients Enrolled

Media Library

Baricitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05858515 — Phase 3
Post-COVID Syndrome Research Study Groups: Intervention #1, Placebo
Post-COVID Syndrome Clinical Trial 2023: Baricitinib Highlights & Side Effects. Trial Name: NCT05858515 — Phase 3
Baricitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05858515 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What potential risks or side effects might patients encounter with Intervention #1?

"Our team at Power has evaluated the safety of Intervention #1 to be a 2, as this Phase 2 trial only possesses limited evidence demonstrating its security but lacks any data that would attest to its efficacy."

Answered by AI

Are additional volunteers being sought for this trial?

"The data accessible on clinicaltrials.gov reveals that this particular medical trial, which first opened its recruitment doors in June 1st of 2023, is no longer accepting new participants at the moment. Nevertheless, there are 684 other active studies seeking patients as an alternative option."

Answered by AI

Which geographical areas are this study's operations centered in?

"Yale University in New Haven, Connecticut; Emory University in Atlanta, Georgia; and the University of Minnesota in Minneapolis, Minnesota are among the sites presently recruiting for this study. In total there are 6 additional locations as well."

Answered by AI

What is the ultimate goal of this trial?

"This 6 month clinical trial will gauge the value of diversity in enrollment. Secondary objectives include examining premature study discontinuation, global neuropsychological function and everyday cognition changes between baricitinib and placebo groups from baseline to week 12."

Answered by AI

Who else is applying?

What site did they apply to?
Vanderbilt University
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
REVERSE-Long COVID-19 With Baricitinib Study
Wes Ely 2024. "REVERSE-Long COVID-19 With Baricitinib Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05858515.
All > Survivor Corps
~367 spots leftby Dec 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top